Outlook Therapeutics $55M Public Offering

MiNK Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for retinal diseases, announced the pricing of an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants to purchase up to 55,555,556 shares. The combined public offering price is $0.99 per share and warrant. The warrants have an exercise price of $1.10 per share, are immediately exercisable, and expire in five years. The company granted underwriters a 30-day option to purchase up to 8,333,333 additional shares and/or warrants. The offering is expected to close on August 14, 2026. Piper Sandler Companies and BTIG are joint bookrunning managers, with Brookline Capital Markets, a division of Meritz Securities, acting as lead manager. Gross proceeds are expected to be approximately $55 million, before underwriting discounts and commissions. Net proceeds will be used to support the commercial launch of LYTENAVA in the United States, as well as for working capital and general corporate purposes. The offering is made under a shelf registration statement on Form S-3 filed with the SEC on March 28, 2024, and declared effective on April 5, 2024.